Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels.

We examined anti-tumor effects of zoledronic acid (ZOL), one of the bisphosphonates agents clinically used for preventing loss of bone mass, on human mesothelioma cells bearing the wild-type p53 gene. ZOL-treated cells showed activation of caspase-3/7, -8 and -9, and increased sub-G1 phase fractions...

Full description

Bibliographic Details
Main Authors:	Shinya Okamoto, Yuanyuan Jiang, Kiyoko Kawamura, Masato Shingyoji, Toshihiko Fukamachi, Yuji Tada, Yuichi Takiguchi, Koichiro Tatsumi, Hideaki Shimada, Kenzo Hiroshima, Hiroshi Kobayashi, Masatoshi Tagawa
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3610651?pdf=render

Internet

http://europepmc.org/articles/PMC3610651?pdf=render

Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels.

Internet

Similar Items